ATAI Life Sciences N.V [ATAI] stock is trading at $3.97, down -1.98%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ATAI shares have lost -3.87% over the last week, with a monthly amount glided 12.46%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ATAI Life Sciences N.V [NASDAQ: ATAI] stock has seen the most recent analyst activity on July 29, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $14. Previously, H.C. Wainwright reaffirmed its Buy rating on November 18, 2024, and dropped its price target to $10. On April 03, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $6 on the stock. Loop Capital started tracking the stock assigning a Buy rating and suggested a price target of $18 on November 01, 2022. Maxim Group initiated its recommendation with a Buy and recommended $25 as its price target on November 30, 2021. ROTH Capital started tracking with a Buy rating for this stock on November 11, 2021, and assigned it a price target of $32. In a note dated October 18, 2021, H.C. Wainwright initiated a Buy rating and provided a target price of $40 on this stock.
ATAI Life Sciences N.V [ATAI] stock has fluctuated between $1.03 and $4.40 over the past year. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. ATAI Life Sciences N.V [NASDAQ: ATAI] shares were valued at $3.97 at the most recent close of the market. An investor can expect a potential return of 25.94% based on the average ATAI price forecast.
Analyzing the ATAI fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -42.66%, Pretax Profit Margin comes in at -51.8%, and Net Profit Margin reading is -51.71%. To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -0.86 and Total Capital is -0.6. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.82 points at the first support level, and at 3.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.17, and for the 2nd resistance point, it is at 4.37.
Ratios To Look Out For
For context, ATAI Life Sciences N.V’s Current Ratio is 4.02. In addition, the Quick Ratio stands at 4.02 and the Cash Ratio stands at 2.42. Considering the valuation of this stock, the price to sales ratio is 2578.55, the price to book ratio is 5.86.
Transactions by insiders
Recent insider trading involved Apeiron Investment Group Ltd., 10% Owner, that happened on Aug 14 ’25 when 8.68 million shares were purchased. Officer, SAHIL KIRPEKAR completed a deal on Jul 02 ’25 to buy 83332.0 shares. Meanwhile, Officer SAHIL KIRPEKAR bought 0.11 million shares on Jul 01 ’25.
